Oral Cyclic Peptides: Molecule Design and Delivery Strategies
Oral Cyclic Peptides
This guide separates oral cyclic peptide drug programs from formulation, delivery, and manufacturing services. Start by checking the molecule's structural class and site of action, then compare the evidence supporting its oral development strategy.
Questions to ask first
- Is the lead molecule a cyclic peptide, or an adjacent linear peptide or oral delivery program?
- Does the disclosed evidence come from laboratory, animal, or human studies, and was the same formulation used?
- Does the company offer its own drug candidates, technology for licensing, or development and manufacturing services for clients?
Key terms
- Cyclic peptide
- A peptide with a cyclic backbone structure; oral administration alone does not establish that a molecule is a cyclic peptide.
- Oral delivery
- A molecular, formulation, or device strategy for oral administration, with a distinction between systemic absorption and local gastrointestinal action.
- Products versus services
- A product pipeline describes drug candidates a company develops; service capabilities describe work it can perform for outside clients.
Evidence and scope
The topic includes adjacent delivery approaches relevant to oral cyclic peptide development, with their scope identified in individual entries. Animal pharmacokinetics, platform descriptions, and collaboration announcements do not replace human evidence. Results from different molecules, formulations, doses, and study conditions should not be used as a simple performance ranking. The current map covers 79 developers, platforms, service providers, and regional commercial partners; company counts are not counts of independent drugs. Unconfirmed cyclization, human oral exposure, and financing details remain explicitly marked. Discontinued programs are distinguished from active pipelines. Channel updates can be browsed over the past 12 months.
Technology snapshot: 2026-11-03 · Research methods
